StocksMedium•9 November 2026•
1 min read
Larimar Therapeutics Completes Rolling BLA Submission to FDA for Nomlabofusp
Key Facts
1Larimar Therapeutics completed its rolling Biologics License Application (BLA) submission to the FDA for nomlabofusp.
Larimar Therapeutics completed its rolling Biologics License Application (BLA) submission to the FDA for nomlabofusp. Benzinga reported that the company is seeking accelerated approval for the drug, which is designed to treat Friedreich's ataxia.
The submission represents a critical regulatory milestone toward introducing the first protein replacement therapy for this condition to the US market. Regarding equity performance, Larimar Therapeutics, trading under the ticker LRMR, closed at $2.39 on November 6, 2026.